Logo image of EVT.DE

EVOTEC SE (EVT.DE) Stock Fundamental Analysis

FRA:EVT - Deutsche Boerse Ag - DE0005664809 - Common Stock - Currency: EUR

7.252  +0.44 (+6.46%)

Fundamental Rating

2

Taking everything into account, EVT scores 2 out of 10 in our fundamental rating. EVT was compared to 18 industry peers in the Life Sciences Tools & Services industry. EVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EVT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EVT has reported negative net income.
In the past year EVT had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: EVT reported negative net income in multiple years.
EVT had a positive operating cash flow in each of the past 5 years.
EVT.DE Yearly Net Income VS EBIT VS OCF VS FCFEVT.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

The Return On Assets of EVT (-10.64%) is worse than 83.33% of its industry peers.
Looking at the Return On Equity, with a value of -22.69%, EVT is doing worse than 83.33% of the companies in the same industry.
Industry RankSector Rank
ROA -10.64%
ROE -22.69%
ROIC N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
EVT.DE Yearly ROA, ROE, ROICEVT.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

Looking at the Gross Margin, with a value of 13.62%, EVT is doing worse than 88.89% of the companies in the same industry.
EVT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
EVT.DE Yearly Profit, Operating, Gross MarginsEVT.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

4

2. Health

2.1 Basic Checks

EVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
EVT has more shares outstanding than it did 1 year ago.
EVT has more shares outstanding than it did 5 years ago.
EVT has a better debt/assets ratio than last year.
EVT.DE Yearly Shares OutstandingEVT.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
EVT.DE Yearly Total Debt VS Total AssetsEVT.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of 1.40, we must say that EVT is in the distress zone and has some risk of bankruptcy.
EVT's Altman-Z score of 1.40 is on the low side compared to the rest of the industry. EVT is outperformed by 77.78% of its industry peers.
EVT has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.46, EVT is doing good in the industry, outperforming 61.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Altman-Z 1.4
ROIC/WACCN/A
WACC6.61%
EVT.DE Yearly LT Debt VS Equity VS FCFEVT.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

EVT has a Current Ratio of 2.03. This indicates that EVT is financially healthy and has no problem in meeting its short term obligations.
EVT has a better Current ratio (2.03) than 83.33% of its industry peers.
EVT has a Quick Ratio of 1.93. This is a normal value and indicates that EVT is financially healthy and should not expect problems in meeting its short term obligations.
EVT's Quick ratio of 1.93 is amongst the best of the industry. EVT outperforms 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 2.03
Quick Ratio 1.93
EVT.DE Yearly Current Assets VS Current LiabilitesEVT.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for EVT have decreased strongly by -136.17% in the last year.
Looking at the last year, EVT shows a small growth in Revenue. The Revenue has grown by 1.50% in the last year.
EVT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.29% yearly.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.44%
Revenue 1Y (TTM)1.5%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-4.19%

3.2 Future

EVT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.33% yearly.
The Revenue is expected to grow by 9.40% on average over the next years. This is quite good.
EPS Next Y74%
EPS Next 2Y37.84%
EPS Next 3Y32.3%
EPS Next 5Y18.33%
Revenue Next Year8.33%
Revenue Next 2Y9.65%
Revenue Next 3Y9.45%
Revenue Next 5Y9.4%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EVT.DE Yearly Revenue VS EstimatesEVT.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
EVT.DE Yearly EPS VS EstimatesEVT.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVT.DE Price Earnings VS Forward Price EarningsEVT.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EVT is valued expensively inside the industry as 83.33% of the companies are valued cheaper.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 109.42
EVT.DE Per share dataEVT.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

EVT's earnings are expected to grow with 32.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.84%
EPS Next 3Y32.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EVT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOTEC SE

FRA:EVT (7/25/2025, 7:00:00 PM)

7.252

+0.44 (+6.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-17 2025-04-17/bmo
Earnings (Next)08-13 2025-08-13/bmo
Inst Owners57.36%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.58B
Analysts76.67
Price Target10.38 (43.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.02%
Min Revenue beat(2)-5.1%
Max Revenue beat(2)-0.93%
Revenue beat(4)0
Avg Revenue beat(4)-4.55%
Min Revenue beat(4)-6.12%
Max Revenue beat(4)-0.93%
Revenue beat(8)2
Avg Revenue beat(8)-1.47%
Revenue beat(12)5
Avg Revenue beat(12)2.41%
Revenue beat(16)9
Avg Revenue beat(16)4.66%
PT rev (1m)-0.87%
PT rev (3m)-17.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-77.78%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.27
P/FCF N/A
P/OCF 74.45
P/B 2.82
P/tB 4.26
EV/EBITDA 109.42
EPS(TTM)-1.11
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)0.1
OCFY1.34%
SpS2.22
BVpS2.57
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.64%
ROE -22.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.62%
FCFM N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
F-Score4
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Debt/EBITDA 18.85
Cap/Depr 113.07%
Cap/Sales 14.58%
Interest Coverage N/A
Cash Conversion 156.03%
Profit Quality N/A
Current Ratio 2.03
Quick Ratio 1.93
Altman-Z 1.4
F-Score4
WACC6.61%
ROIC/WACCN/A
Cap/Depr(3y)186.39%
Cap/Depr(5y)182.37%
Cap/Sales(3y)22.79%
Cap/Sales(5y)21.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.44%
EPS Next Y74%
EPS Next 2Y37.84%
EPS Next 3Y32.3%
EPS Next 5Y18.33%
Revenue 1Y (TTM)1.5%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-4.19%
Revenue Next Year8.33%
Revenue Next 2Y9.65%
Revenue Next 3Y9.45%
Revenue Next 5Y9.4%
EBIT growth 1Y-3.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.54%
EBIT Next 3Y53.1%
EBIT Next 5Y35.28%
FCF growth 1Y36.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50%
OCF growth 3Y-46.98%
OCF growth 5Y-15.47%